View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharma Mar 過去の業績過去 基準チェック /26Pharma Marは、平均年間38.9%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間18.8% 10.5%収益成長率で 成長しています。 Pharma Marの自己資本利益率は13.3%であり、純利益率は16.3%です。主要情報38.91%収益成長率38.59%EPS成長率Biotechs 業界の成長12.91%収益成長率10.48%株主資本利益率13.27%ネット・マージン16.25%前回の決算情報31 Mar 2023最近の業績更新お知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.すべての更新を表示Recent updatesお知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024お知らせ • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.お知らせ • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.お知らせ • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).収支内訳Pharma Mar の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BMV:PHM1 N 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Mar 2317729428531 Dec 2219649438330 Sep 2223184428330 Jun 2223385428431 Mar 2223291417631 Dec 2123093407230 Sep 2118863346130 Jun 2120067355831 Mar 2122291355631 Dec 20270137365430 Sep 20246147374830 Jun 20214124384731 Mar 2016672394831 Dec 1986-9385130 Sep 19136-27585830 Jun 1984-37386131 Mar 19154-24596931 Dec 18109-17397430 Sep 18189-16668030 Jun 18128-204411931 Mar 18179-26657931 Dec 17159-28587930 Sep 17182-22677730 Jun 17186-18747831 Mar 17184-19677831 Dec 16181-24687830 Sep 16187-18687530 Jun 16188-10716031 Mar 16190-7706631 Dec 151947696031 Dec 1417513604631 Dec 13741259031 Dec 126610600質の高い収益: PHM1 Nは 高品質の収益 を持っています。利益率の向上: PHM1 Nの現在の純利益率 (16.3%)は、昨年(39.1%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PHM1 N過去 5 年間で収益を上げており、収益は年間38.9%増加しています。成長の加速: PHM1 Nは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: PHM1 Nは過去 1 年間で収益成長率がマイナス ( -68.2% ) となったため、 Biotechs業界平均 ( 15.2% ) と比較することが困難です。株主資本利益率高いROE: PHM1 Nの 自己資本利益率 ( 13.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/12 19:34終値2023/03/16 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharma Mar, S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Jaime EscribanoBanco SantanderPatricia CifuentesBestinver Sociedad De Valores, S.AKambiz YazdiBTIG9 その他のアナリストを表示
お知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024
お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.
お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.
お知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024
お知らせ • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.
お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.
お知らせ • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.
お知らせ • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.
Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).